Bio-Path Holdings Inc. (NASDAQ: BPTH) stock surged by 8.76% in the current market trading. Bio-Path is a biotech firm working on DNAbilize, a new technique that has resulted in a pipeline of RNAi nanoparticle medicines that may be given by intravenous infusion.
The US Patent and Trademark Office has awarded a new patent to BPTH for its BP1003 program, which is a novel liposome-incorporated oligodeoxynucleotide inhibitor against Signal Transduction and Activator of Transcription-3 (STAT3). “P-Ethoxy Nucleic Acids for STAT3 Inhibition,” according to the patent (US Patent No. 11,041,153).
The new patent expands on previous patents that cover the platform technology for DNAbilize, BPTH’s new RNAi nanoparticle medicines. DNAbilize is a patent-pending liposomal nanoparticle delivery and antisense technique that uses a basic intravenous transfusion to systemically distribute nucleic acid medicines all through the body.
In cancer cells, STAT3 is hyperactive. Cancer is characterized by tumor cells’ ability to grow uncontrolled, defy apoptosis, promote vascular development, and infiltrate distant organs. STAT3 is a gene regulator that controls the expression of genes implicated in cancer. Tumors’ capacity to elude immune monitoring and prevent elimination by the immune system has lately received widespread support in the cancer research community. At several levels, STAT3, which is a point of confluence for numerous oncogenic pathways, has emerged as a key modulator of tumor immune evasion.
Peter Nielsen, President, and CEO of Bio-Path Holdings stated,
Bio-increasing Path’s intellectual property collection remains to be a valuable asset, and the inclusion of this new patent adds to that important as they progress their newest pipeline product, BP1003. This mechanistic patent protects their position and emphasizes the uniqueness of BP1003’s ability to inhibit STAT3 which is a protein that has been found to be overexpressed in a number of complicated cancers, including pancreatic cancer, non-small cell lung cancer, and acute myeloid leukemia (AML), among others. BPTH is excited to go on with the development of BP1003 in pancreatic cancer, which they plan to start next year.